Search results
Results From The WOW.Com Content Network
The firm, in collaboration with the Government of Odisha, is establishing another facility at Odisha Biotech Park in Bhubaneswar to commence Covaxin production by June 2022. [ 14 ] [ 15 ] In December 2020, Ocugen entered into a partnership with Bharat Biotech to co-develop and exclusively commercialise Covaxin in the US market; [ 16 ] [ 17 ] in ...
The authors came to the conclusion that no further trials of hydroxychloroquine or chloroquine for treatment of COVID-19 should be carried out. [58] On 26 April 2021, in its amended clinical management protocol for COVID-19, the Indian Ministry of Health lists hydroxychloroquine for use in patients during the early course of the disease. [23]
The first cases of COVID-19 in India were reported on 30 January 2020 in three towns of Kerala, among three Indian medical students who had returned from Wuhan, the epicenter of the pandemic. [10] [11] [12] Lockdowns were announced in Kerala on 23 March, and in the rest of the country on 25 March. Infection rates started to drop in September. [13]
The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021 and is estimated to reach $130 billion by 2030. [1] India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports.
Bebtelovimab is a neutralizing human immunoglobulin G1 (IgG1) monoclonal antibody, isolated from a patient who has recovered from the Coronavirus disease 2019 (COVID-19), directed against the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against COVID-19.
The government is stepping up its efforts to fund vaccine studies and production for at least three of five frontrunner candidates — something that Dr. Anthony Fauci told Yahoo Finance will be ...
The beauty of American medication is that it is both high quality and often the first of its kind on the market. Imagine the endless possibilities when we unleash — rather than hinder ...
The government launched several initiatives to address these shortages, including converting public buildings into COVID-19 care centers and increasing domestic production of medical supplies. Unfortunately, the second wave of COVID-19 hit India in April 2021, resulting in even higher numbers of cases and deaths than the first wave.